Skip to content
GLP-1 Savers
Menu

Head-to-head · Value Score

CoreAge Rx vs Luma Meds

Two GLP-1 deals, scored on the same six factors. CoreAge Rx lands a Value Score of 93, Luma Meds a 74. Here's who gives you the honest lower price — and where each one bites back.

★ Better value

CoreAge Rx

#1 · Grade A+ · Best Value

Est. first month

$149/mo

Save ~89% vs brand-name
Get this deal Full CoreAge Rx review →
VS

Luma Meds

#157 · Grade C+ · Watch List

Est. first month

From $140/mo (3-month plan, compounded)

Save ~90% vs brand-name
Get this deal Full Luma Meds review →

The verdict

Better value: CoreAge Rx

CoreAge Rx takes it on Value Score, 93 to 74 an est. $149/mo first month, with no teaser step-up baked in. Luma Meds isn't out of it: People who want a LegitScript-certified compounded GLP-1 plan with free shipping and provider support.

CoreAge Rx is also our overall #1 pick across the whole deals board — a flat, all-in price on both molecules in all 50 states. That's why it wins here on the score, not just this matchup.

Deal-by-deal

The numbers that decide it. Green ✓ marks the stronger side on each line.

DealCoreAge RxLuma Meds
Value Score93 (A+)74 (C+)
Est. first month$149/moFrom $140/mo (3-month plan, compounded)
Save vs brand-name~89%~90%
Semaglutide$149/moFrom $140/mo (3-month plan, compounded)
Tirzepatide$349/moFrom $166/mo (3-month plan, compounded)
Both moleculesYesYes
PricingFlat — no step-upWatch
CoverageAll 50 statesCoverage not published

Factor by factor

The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.

88
Lowest Real Price
84
CoreAge Rx: 88. Luma Meds: 84.
98
No Teaser-Rate Bait
62
CoreAge Rx: 98. Luma Meds: 62.
98
Nationwide Availability
45
CoreAge Rx: 98. Luma Meds: 45.
95
Both Molecules
92
CoreAge Rx: 95. Luma Meds: 92.
95
Easy Cancellation
68
CoreAge Rx: 95. Luma Meds: 68.
84
Reputation
80
CoreAge Rx: 84. Luma Meds: 80.

CoreAge Rx

The honest lowest price: both molecules at one flat, all-in monthly rate that never steps up after month one.

Why it's a deal

  • Flat, all-in monthly price with no intro-rate step-ups after month one
  • Both compounded semaglutide and tirzepatide on one account
  • Available in all 50 states
  • Straightforward, low-friction cancellation — no lock-in

The fine print

  • Not the rock-bottom sticker — a couple of teaser tiers advertise lower month-one rates
  • No FDA-approved brand-name option (compounded only)
  • Does not yet publicly name its 503A/B pharmacy partner

Luma Meds

Fully online compounded GLP-1 telehealth offering semaglutide and tirzepatide injections from FDA-regulated 503A and 503B compounding pharmacies.

Why it's a deal

  • LegitScript certified — a credibility mark fewer compounded GLP-1 providers carry
  • Free discreet shipping and unlimited 24/7 support on every plan
  • Compounded semaglutide and tirzepatide from FDA-regulated 503A/503B pharmacies
  • '100,000+ members treated' claim with physician-supervised online care
  • 3-month bundle pricing brings semaglutide as low as $140/mo

The fine print

  • Compounding pharmacy partner not publicly named
  • States available not published
  • Monthly semaglutide ($249/mo) is above many lower-cost compounded competitors
  • No oral formulation options listed
  • Compounded medications are not FDA-approved
Get the CoreAge Rx deal Get the Luma Meds deal

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.

Neither one the right fit? Every program that outscores CoreAge Rx is ranked on the CoreAge Rx alternatives board, and the same list for the other side is on alternatives to Luma Meds.

More head-to-heads

← All comparisons

Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.